FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381337102> ?p ?o ?g. }

• W4381337102 abstract "Abstract Atopic dermatitis (AD) is a common, chronic immuno-inflammatory skin disorder that commonly arises during childhood. Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate AD. This study aims to evaluate the efficacy and safety of crisaborole ointment, 2%, in pediatric Chinese and Japanese patients aged 2–17 years with mild-to-moderate AD. This post hoc analysis of a double-blind, vehicle-controlled, phase 3 study (CrisADe CLEAR; NCT04360187) evaluated the safety and efficacy of crisaborole in Chinese and Japanese patients aged ≥2 years with mild-to-moderate AD (involving ≥5% treatable body surface area). Patients were randomly assigned 2 : 1 to receive crisaborole or vehicle, respectively, twice-daily for 28 days. In this analysis, subgroups consisting of Chinese and Japanese patients aged 2–6 years, 2–11 years, and 12–17 years from the overall population were assessed. Efficacy endpoints included percent change from baseline in Eczema Area and Severity Index (EASI) total score at Day 29, improvement in Investigator’s Static Global Assessment (ISGA) score [score of 0 (clear) or 1 (almost clear)] at Day 29, success per ISGA (score of 0 or 1 with a ≥2-grade improvement from baseline) at Day 29, and change from baseline in Peak Pruritus Numerical Rating Scale (PP-NRS; used with permission from Regeneron Pharmaceuticals, Inc., and Sanofi) score at Week 4 (patients ≥12 years only). Safety was also assessed. Of 391 patients in the overall study, 93 were aged 2–6 years, 99 were aged 7–11 years, and 40 were aged 12–17 years. A greater reduction in percent change from baseline in EASI total score at Day 29 was shown in crisaborole- vs. vehicle-treated patients for patients aged 2–6 years and the overall population, with comparable reductions in other age subgroups (ClinicalTrials.gov, NCT04360187). Patients in the crisaborole group vs. the vehicle group had higher rates of ISGA improvement (age 2–6 subgroup) and success per ISGA (age 12–17 subgroup); comparable response rates were seen in other age subgroups (ClinicalTrials.gov, NCT04360187). Patients who received crisaborole showed a greater reduction vs. those who received vehicle in change from baseline in PP-NRS score at Week 4 in the overall population, with a comparable reduction seen in patients aged ≥12 years (ClinicalTrials.gov, NCT04360187). Crisaborole-treated patients in the overall population and each age subgroup had consistent but comparable improvement in all primary and key secondary efficacy endpoints. In patients aged 2–6 years, 55.4% and 62.2% of those who received crisaborole and vehicle, respectively, experienced all-cause treatment-emergent adverse events (TEAEs). All-cause TEAEs occurred in 52.2% and 34.4% of patients aged 7–11 years who received crisaborole and vehicle, respectively; in the aged 12–17 years subgroup, 36% and 40% of patients who received crisaborole and vehicle experienced all-cause TEAEs, respectively. The TEAEs occurring in ≥1% of patients across all subgroups included atopic dermatitis and treatment-related application site pain. Application site pain was most frequently reported in the face and neck. Most TEAEs were mild. There were no new safety findings. Crisaborole was effective and well tolerated in Chinese and Japanese patients aged 2–17 years with mild-to-moderate AD." @default.
• W4381337102 created "2023-06-21" @default.
• W4381337102 creator A5004147147 @default.
• W4381337102 creator A5019631452 @default.
• W4381337102 creator A5027458726 @default.
• W4381337102 creator A5027748236 @default.
• W4381337102 creator A5027806527 @default.
• W4381337102 creator A5030937777 @default.
• W4381337102 creator A5044622075 @default.
• W4381337102 creator A5052909306 @default.
• W4381337102 creator A5068452706 @default.
• W4381337102 creator A5077063251 @default.
• W4381337102 creator A5081882759 @default.
• W4381337102 date "2023-06-01" @default.
• W4381337102 modified "2023-10-03" @default.
• W4381337102 title "434 Efficacy and safety of crisaborole ointment, 2%, in Chinese and Japanese pediatric patients aged 2–17 years with mild-to-moderate atopic dermatitis" @default.
• W4381337102 doi "https://doi.org/10.1093/bjd/ljad162.054" @default.
• W4381337102 hasPublicationYear "2023" @default.
• W4381337102 type Work @default.
• W4381337102 citedByCount "0" @default.
• W4381337102 crossrefType "journal-article" @default.
• W4381337102 hasAuthorship W4381337102A5004147147 @default.
• W4381337102 hasAuthorship W4381337102A5019631452 @default.
• W4381337102 hasAuthorship W4381337102A5027458726 @default.
• W4381337102 hasAuthorship W4381337102A5027748236 @default.
• W4381337102 hasAuthorship W4381337102A5027806527 @default.
• W4381337102 hasAuthorship W4381337102A5030937777 @default.
• W4381337102 hasAuthorship W4381337102A5044622075 @default.
• W4381337102 hasAuthorship W4381337102A5052909306 @default.
• W4381337102 hasAuthorship W4381337102A5068452706 @default.
• W4381337102 hasAuthorship W4381337102A5077063251 @default.
• W4381337102 hasAuthorship W4381337102A5081882759 @default.
• W4381337102 hasConcept C126322002 @default.
• W4381337102 hasConcept C16005928 @default.
• W4381337102 hasConcept C187212893 @default.
• W4381337102 hasConcept C197934379 @default.
• W4381337102 hasConcept C2778329239 @default.
• W4381337102 hasConcept C2780699399 @default.
• W4381337102 hasConcept C67761136 @default.
• W4381337102 hasConcept C71924100 @default.
• W4381337102 hasConceptScore W4381337102C126322002 @default.
• W4381337102 hasConceptScore W4381337102C16005928 @default.
• W4381337102 hasConceptScore W4381337102C187212893 @default.
• W4381337102 hasConceptScore W4381337102C197934379 @default.
• W4381337102 hasConceptScore W4381337102C2778329239 @default.
• W4381337102 hasConceptScore W4381337102C2780699399 @default.
• W4381337102 hasConceptScore W4381337102C67761136 @default.
• W4381337102 hasConceptScore W4381337102C71924100 @default.
• W4381337102 hasIssue "Supplement_3" @default.
• W4381337102 hasLocation W43813371021 @default.
• W4381337102 hasOpenAccess W4381337102 @default.
• W4381337102 hasPrimaryLocation W43813371021 @default.
• W4381337102 hasRelatedWork W2044086330 @default.
• W4381337102 hasRelatedWork W2916274906 @default.
• W4381337102 hasRelatedWork W2995377367 @default.
• W4381337102 hasRelatedWork W3134278412 @default.
• W4381337102 hasRelatedWork W3194042231 @default.
• W4381337102 hasRelatedWork W3195909406 @default.
• W4381337102 hasRelatedWork W4320485560 @default.
• W4381337102 hasRelatedWork W4377221388 @default.
• W4381337102 hasRelatedWork W4381336844 @default.
• W4381337102 hasRelatedWork W4386437785 @default.
• W4381337102 hasVolume "188" @default.
• W4381337102 isParatext "false" @default.
• W4381337102 isRetracted "false" @default.
• W4381337102 workType "article" @default.